Skip to content
Medical Health Aged Care

Researchers to test the impact of a special healthy diet on Crohn’s disease

Monash University 2 mins read

Volunteers are needed to test a diet that researchers hope can improve the lives of those living with Crohn’s disease, a debilitating condition requiring life-long immunosuppression drugs and/or surgery.

 

The Monash University-led study will investigate whether a newly developed diet can reduce inflammation in Crohn’s Disease.

 

Inflammatory bowel disease, which includes Crohn’s disease, affects an estimated 100,000 Australians in total, including about one in 250 people aged 5-40, and this number is increasing. 

 

It is a chronic, lifelong relapsing and remitting disease. A diet was developed that can reduce symptoms and inflammation, but it is a liquid diet, so can be very difficult to maintain long-term.

 

Exclusive Enteral Nutrition has been used for about 30 years and involves drinking a nutritionally balanced liquid at the exclusion of all other foods and fluids except water for 6-12 weeks. It is not a permanent solution.

 

The new study will provide freshly made healthy food for four weeks to participants who have active Crohn's disease and are on stable medical therapy but have ongoing intestinal inflammation and symptoms. Participants will be allocated to one of two diets that follow healthy eating guidelines but differ in ingredients.

 

PhD candidate Jessica Fitzpatrick, a dietitian in the Monash University Central Clinical School’s Department of Gastroenterology, said an increase in Crohn’s disease and the frequency of flare ups had been attributed to diet, so a suitable food based diet could help.

 

“The traditional treatment for Crohn's disease is life-long medical immunosuppression or surgery, for people who are usually diagnosed between the ages of 15 to 30,” she said.


There is no known cure. Dietary therapy can work in Crohn's Disease as we have one dietary therapy known to induce remission in Crohn's disease, but it is a completely liquid diet that some adults have difficulty in following.”

 

Ms Fitzpatrick said those with Crohn’s often found it difficult to participate actively in its management. Many ended up requiring hospital treatment and had poor access to multidisciplinary chronic disease care, which also impacted upon them psychologically.

 

“Having a dietary therapy to help control symptoms and inflammation that is based on high quality evidence may allow patients to have some control over their disease and improve their overall health and wellbeing,” she said.

 

The study needs 40 participants aged between 18 and 60 who live in or are willing to travel to Melbourne for two study appointments at the Alfred Hospital. They would need to eat the study food to the exclusion of all other foods, have two blood/urine/stool tests and intestinal ultrasound.

 

They will record their symptoms and how much of the study food they are eating throughout.

 

Anyone interested in participating should contact Jessica Fitzpatrick at jessica.fitzpatrick1@monash.edu

 

About Crohn’s disease

Crohn's disease is a condition of inflammation in the gastrointestinal tract that causes abdominal pain, altered bowel habits, fatigue, nutritional deficiencies and has a large impact on patients’ quality of life and wellbeing. For young people to be prescribed life-long immunosuppression often leads to side effects, risks and medication failure. In 2019, the Australian Government and partners developed an Inflammatory Bowel Disease National Action Plan to improve the care of patients with Crohn's disease around Australia.

 

For media enquiries please contact:

 

Monash University

Cheryl Critchley - Communications Manager (medical)
E:
cheryl.critchley@monash.edu

T: +61 (0) 418 312 596

 

For more Monash media stories, visit our news and events site 


For general media enquiries please contact:
Monash Media
E: 
media@monash.edu
T: +61 (0) 3 9903 4840

 

***ENDS***

 

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.